Status:
UNKNOWN
A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients
Lead Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions:
NHL
Eligibility:
All Genders
18-99 years
Brief Summary
Observational prospective study. Patients with DLBCL and HGBCL will be enrolled in the study to collect samples for developing a blood based assay allowing biomarker driven treatment in the future.
Detailed Description
The rationale of this study is that, due to the lack of successful salvage options, first-line treatment outcome needs to be improved. To make this possible, a crucial condition is optimal identificat...
Eligibility Criteria
Inclusion
- Patients diagnosed with newly diagnosed DLBCL (including HGBCL- NOS and HGBCL-DH) according to WHO classification 2016
- Ann Arbor stage II-IV
- Patients intended to be treated with 6 cycles R-CHOP (or DA-EPOCH-R) as first-line treatment (successive inclusion in HOVON 151 or HOVON 152 is possible)
- Age ≥ 18 years
Exclusion
- \- Patients with limited stage I, II disease planned to receive 3 cycles of R-CHOP + radiotherapy, or 4 x R-CHOP+ 2R
Key Trial Info
Start Date :
March 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04139252
Start Date
March 17 2020
End Date
June 1 2023
Last Update
April 26 2023
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands
2
NL-Alkmaar-NWZ
Alkmaar, Netherlands
3
NL-Almelo-ZGTALMELO
Almelo, Netherlands
4
NL-Almere-FLEVOZIEKENHUIS
Almere Stad, Netherlands